Disc’s once-spurned rare disease drug to get a second chance at approval

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 19 Oct, 16:27 UTC

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

policyscience

Sources

• T2Disc’s once-spurned rare disease drug to get a second chance at approvalBioPharma Dive / Healthcare Dive / MedTech Dive19 Oct, 16:27